Scans showing enhanced drug delivery to laboratory rats' brain tumors -- The University of Southern Mississippi's Business and Innovation Assistance Center is assisting Thermally Targeted Therapeutics, Inc. with obtaining SBIR-STTR funding support and technology commercialization for its highly innovative approach to enhancing chemotherapy drug delivery with less harmful side effects.
The Mississippi - Federal and State Technology Partnership program (MS-FAST) was established in 2001 to assist Mississippi’s small high-tech firms to better compete in the SBIR (Small Business Innovation Research) and STTR (Small Business Technology Transfer) programs. SBIR and STTR are two competitively awarded, highly specialized forms of federal funding for small firms (less than 500 employees) to perform cutting-edge R&D that addresses the nation's (government and industry) most critical scientific and engineering needs. These needs span the technology spectrum -- from aviation and agriculture to medicine and manufacturing. Annually over $2.4 billion in contracts and grants are awarded to small businesses by the 11 federal agencies participating in these programs. Lead by the University of Southern Mississippi working with its Mississippi Research Consortium members (Jackson State University, Mississippi State University, University of Mississippi and the University of Mississippi Medical Center), and supported in part by Innovate Mississippi, MS-FAST provides the following assistance to Mississippi companies:
To view presentations on MS-FAST and related projects, visit our presentations page.
For more information on the federal SBIR-STTR programs visit: www.sbir.gov
Support provided by:
"This U.S. Small Business Administration (SBA) Cooperative Agreement is partially funded by the SBA. SBA's funding is not an endorsement of any products, opinions, or services. All SBA funded programs are extended to the public on a nondiscriminatory basis."